Article Text

Download PDFPDF

2022-RA-1486-ESGO Characteristics, treatment patterns and outcomes of patients with newly diagnosed advanced ovarian cancer (aOC) in England
  1. Angela Whittle1,
  2. Betina Blak1,
  3. Amy Zalin-Miller2,3 and
  4. Orlaith Condon1
  1. 1Medical affairs, Oncology Business Unit, AstraZeneca UK Ltd, London, UK
  2. 2Health Data Insight, Cambridge, UK
  3. 3National Disease Registration Service at NHS Digital, Cambridge, UK


Introduction/Background Personalised care and targeted therapy approaches in aOC have evolved during the last decade with introduction of bevacizumab to platinum-doublet chemotherapy being one of these early advances during this period. This observational, retrospective database study builds on previously published real-world evidence describing patient characteristics and outcomes in newly diagnosed aOC patients treated with systemic therapy with/without bevacizumab.

Methodology Newly diagnosed aOC patients (stage III/IV) were selected from the National Cancer Registration Dataset 01/08/2014 through 31/12/2018. This work includes patient data collated by the National Disease Registration Service. Patients aged ≥18 years at diagnosis, with no other cancers diagnosed in the five years prior to aOC, treated with systemic anti-cancer therapy (SACT) were included. Follow-up ended 31/12/2019. An algorithm defined probable therapy line occurring after aOC diagnosis. Time to next treatment (TTNT): days from start of first-line therapy to start of second-line therapy. Characteristics, treatment patterns and outcomes were described overall and by a sub-cohort receiving bevacizumab in first-line.

Results In the 8717 patients, median age at first-line therapy start was 68.8 (Inter-Quartile-Range (IQR):59.8–75.7) years, 2968 (34%) were diagnosed at stage IV and 1717 (20%) had recorded performance status (PS) 2–3 during first-line. Total, 5505 (63%) received surgery; 2556 (29%) had surgery before first-line therapy. Median TTNT was 331 (IQR:194–488) days in patients observed receiving second-line (n=4193 (48%)). Total 1833 (21%) received bevacizumab in first-line. This sub-cohort had median age 64.8 (IQR:56.4–71.3) years; 921 (50%) were diagnosed at stage IV; 210 (11%) had recorded PS 2–3 during first-line. Median bevacizumab cycles was 11 (IQR:6–16). Surgery occurred in 1291 (70%) patients, with 420 (23%) receiving surgery before first-line. Median TTNT was 426.5 (IQR:309.5–602) days in patients observed receiving second-line (n=972 (53%)).

Conclusion These observations add to the collective body of evidence regarding the changing treatment landscape in aOC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.